Sponsorizzato
DengYue Medicine (DengYueMed/Hong Kong Dengyue Pharmaceutical Limited), founded in 2019, is located in Hong Kong SAR. DengYue is licensed by the Department of Health of Hong Kong to take photos of pharmaceutical import and export wholesalers, specializing in the import and export of new and specialty drugs as well as isolated drugs in the field of major chronic diseases.
-
-
-
-
-
-
-
Class of 2018
-
-
Aggiornamenti recenti
-
Flyrcado™ : A Breakthrough In Cardiac PET Imaging For Coronary Artery DiseaseIn a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select U.S. markets...0 Commenti 0 condivisioni 188 Views 0 AnteprimaEffettua l'accesso per mettere mi piace, condividere e commentare!
-
Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List PriceIonis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...0 Commenti 0 condivisioni 286 Views 0 Anteprima
-
0 Commenti 0 condivisioni 162 Views 0 Anteprima
Altre storie
Sponsorizzato